Advanced Western Blotting Solutions for Targeted Protein Degradation & Drug Discovery

Simple Western™ provides you critical information to run quantitative DC₅₀ curves with a high throughput workflow while providing you reproducible and quantifiable data. Simple Western assays and their automated Western blotting capabilities enhance accuracy, ensure data quality, and deliver results. Our systems integrate easily in PROTAC^® screening assays while providing you the flexibility of seamless transferability of methods and an open platform.

• Fully automated Western blot analysis
• Quantitative protein expression data
• Multiplex analysis in chemiluminescence and fluorescence channels
• Stellar™ NIR/IR Modules with industry-leading detection sensitivity
• Process up to 25 samples in 3 hours or 96 samples overnight
• Built-in total protein normalization

Boost your screening workflow with Simple Western systems, while running up to 96 samples in a single run! In this application note, 120 samples were screened in just two overnight runs to provide highly quantitative data which allows for an accurate determination of DC₅₀ and D_max. Here, off-the-shelf antibodies from Novus Biologicals and PROTAC^® degraders from Tocris were used to automatically profile PROTAC^®-induced Cereblon neosubstrate degradation.

Simple Western on Jess Steps Up the Accuracy on Dose Response

"I work for a fast-paced drug discovery CRO where our clients expect high-quality data with rapid turnarounds. Jess allows me to accurately assess drug compound potency, and with its high throughput ability I can screen multiple compounds quickly and efficiently."

-Rachel Doidge Ph.D., Senior Research Scientist, Aurelia Bioscience, Biocity, Nottingham, UK

Jess Breaks New Quantitative Ground in New Chemical Entity Screening at TCG Lifesciences

“The quantitative assays and short run times on Jess enable us to generate data faster and be more confident in our results.”

-Tonmoy Sarkar, Ph.D., Senior Research Scientist, TCG Lifesciences

Learn how dCBP-1 will be a useful tool for understanding p300/CBP activity at enhancers in both normal and diseased cells from Christopher J. Ott, PhD, Harvard Medical School.

Are you wanting immunoassay-like quantitation for your Westerns with low sample volume? Get picogram-level sensitivity with just 3 µL of starting material! Learn how fully automated Simple Westerns are being used in labs around the world to quantify Degrader-induced protein knockdown. 

Simple Western Publications on Targeted Protein Degradation Research

Watch Dr. Gary Allenby, CSO at Aurelia Bioscience, who shares how their research team is utilizing automated Western blot systems to rapidly and reproducibly quantify protein knockdown following treatment with Degraders. 

dTAG degradation technology offers a generalizable strategy to degrade, in principle, any intracellular protein of interest. The broad applicability that it offers makes this a useful strategy for exploration and validation of targets, particularly in the context of new Degrader development programs.

The Bio-Techne family of brands offer a unique portfolio of high-quality reagents, instruments and services for researchers working in the rapidly growing field of Targeted Protein Degradation. Our TPD Research Product Guide highlights the tools and services available from Bio-Techne to support your Targeted Protein Degradation research including, Active Degraders, Degrader Building Blocks, Custom Degrader Services, Proteins and Assays for protein degradation. 

PROTAC^® is a registered trademark of Arvinas Operations, Inc., and is used under license

In drug discovery, confirmation of in-cell target engagement is a critical component of the drug development process. Confirming that a drug candidate engages its proposed target in the cell and determining the concentration at which it exerts the desired effect(s) fulfill fundamental criteria for translation to activity and efficacy in its target tissue. Thermal shift assays (TSA) are regularly used by industry and academia to uncover or confirm interactions using purified proteins. Recently, this type of assay has been adapted to a cellular format and is called the cellular thermal shift assay (CETSA). Importantly, by upgrading from a biochemical to a cellular system, biological relevance is preserved.

Dr. Matias Casás Selves, Research Scientist, Drug Discovery Program, Ontario Institute for Cancer Research, developed a CETSA-Simple Western assay to monitor protein stability during drug discovery. This application note highlights quantitative and reproducible CETSA data generated with Simple Western (CETSA-Simple Western). This assay verifies drug–target binding, and given its quantitative nature, the half maximal inhibitory concentration (IC₅₀) is also calculated.